BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma

NCT05538988 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Contractual Issues

Conditions

Mycosis Fungoides

Interventions

DRUG: Cemiplimab

Sponsor

AHS Cancer Control Alberta